Harmony Biosciences
HRMY
102 hedge funds and large institutions have $1.19B invested in Harmony Biosciences in 2021 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 31 increasing their positions, 30 reducing their positions, and 9 closing their positions.
200% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 9
50% more capital invested
Capital invested by funds: $790M → $1.19B (+$396M)
21% more funds holding
Funds holding: 84 → 102 (+18)
5.06% more ownership
Funds ownership: 49.2% → 54.26% (+5.1%)
3% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 30
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$62.4M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$39.9M |
| 3 |
Blackstone Inc
New York
|
+$33.8M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
+$11.3M |
| 5 |
BlackRock
New York
|
+$9.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$44.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$26.2M |
| 3 |
NP
Newlight Partners
New York
|
-$24.7M |
| 4 |
VP
venBio Partners
San Francisco,
California
|
-$14.2M |
| 5 |
ACM
Aisling Capital Management
New York
|
-$8.05M |
HRMY Hedge Fund Activity: Q3 2021 in Review
102 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q3 2021, worth a combined $1.19B — up 50% from $790M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new HRMY positions and 9 closed out — a net gain of 18 holders — while 31 added to existing stakes and 30 trimmed.
The largest buyer was Vanguard Group, adding an estimated $62.4M. The largest seller was Novo Holdings A/S, cutting an estimated $44.5M.
- 102 institutional investors held Harmony Biosciences (HRMY) as of Q3 2021, up from 84 in Q2 2021.
- Funds reported $1.19B of Harmony Biosciences stock for Q3 2021, up 50% quarter-over-quarter.
- 27 funds opened new Harmony Biosciences positions in Q3 2021 and 9 closed out, a net change of +18 holders.
- The largest Harmony Biosciences buyer in Q3 2021 was Vanguard Group, an estimated $62.4M added.
- The largest Harmony Biosciences seller in Q3 2021 was Novo Holdings A/S, an estimated $44.5M sold.
Based on aggregated 13F filings for Q3 2021.